Table 2. Comparison of clinical and laboratory characteristics of IFX responders and nonresponders.
| Variable |
Responders |
Non-responders |
P value | ||
|---|---|---|---|---|---|
| UC (%) | CD (%) | UC (%) | CD (%) | ||
| Disease type | 8 (26.7) | 22 (73.3) | 5 (29.4) | 12 (70.6) | – |
| 30 (63.8) | 17 (36.2) | – | |||
| CDEIS week 0 | – | 17.6±4.7 | – | 18.9±4.3 | 0.43 |
| CDEIS week 14 | – | 9.3±3.4 | – | 17.4±4.7 | <0.001 |
| Mayo endoscopic subscore week 0 | 2.6±0.5 | – | 2.2±0.4 | – | 0.15 |
| Mayo endoscopic subscore week 14 | 1.3±0.5 | – | 2.4±0.5 | – | 0.002 |
| ITL (μg ml−1) week 14 | 5.6±3.6 | 3.5±1.6 | 0.9±1.1 | 1.2±1.1 | |
| 4.1±2.4 | 1.1±1.1 | <0.001 | |||
| ITL within therapeutic window (3–7 μg ml−1) at week 14 | 5 (63) | 12 (55) | 0 (0) | 2 (16) | |
| 17 (57) | 2 (12) | <0.001 | |||
| ITL week 14, ≥0.8 μg/ ml−1 | 8 (100) | 20(91) | 3 (60) | 6 (50) | |
| 28 (93.3) | 9 (52.9) | 0.002 | |||
| Negative ATI week 14 | 8 (100) | 19 (86.4) | 3 (60) | 8 (66.7) | |
| 27 (90) | 11 (64.7) | 0.004 | |||
| CRP (mg/L) week 0 | 34.5±47.3 | 45±43 | 35.1±29 | 42±37 | |
| 42±44 | 40±36 | 0.75 | |||
| CRP (mg/L) week 14 | 5.1±2.5 | 6.6±4.9 | 25.5±33 | 36.6±33 | |
| 6±4.5 | 33±31 | 0.005 | |||
| Mean CRP week 14, <5 mg /l−1 | 7 (87.5) | 16 (72) | 4 (80) | 4 (33) | |
| 23 (76.7) | 8 (47.1) | 0.04 | |||
| FC μg/ g−1 week 0 | 541.1±444 | 612±441 | 477.4±411 | 594.6±392 | |
| 593±435 | 560±406 | 0.86 | |||
| FC μg/ g−1 week 14 | 120.1±91.2 | 146.1±110 | 491.8±555 | 689±378 | |
| 139±107 | 631±429 | <0.001 | |||
| Mean FC week 14, <100 μg/ g−1 | 7 (87.5) | 14 (63.6) | 1 (20) | 0 (0) | |
| 21 (70) | 1 (5.9) | <0.001 | |||
Abbreviations: ATI, antibodies to infliximab; CD, Crohn’s disease; CDEIS, Crohn's disease Endoscopic Index of Severity; FC, fecal calprotectin; IFX, infliximab; ITL, IFX trough level; UC, ulcerative colitis.
Data are shown as N (%) or mean±s.d.